Sozinibercept for Wet AMD Misses Primary Endpoint in Phase 3 COAST Trial

Published Date: 11 Apr 2025

The pivotal trial investigating sozinibercept combination therapy failed to meet the primary endpoint of mean change in BCVA at 52 weeks.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot